Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $33.71 million. The enterprise value is $3.39 million.

Market Cap	33.71M
Enterprise Value	3.39M

Important Dates

The next estimated earnings date is Thursday, May 15, 2025, before market open.

Earnings Date	May 15, 2025
Ex-Dividend Date	n/a

Share Statistics

Opus Genetics has 45.48 million shares outstanding. The number of shares has increased by 23.74% in one year.

Current Share Class	45.48M
Shares Outstanding	45.48M
Shares Change (YoY)	+23.74%
Shares Change (QoQ)	+16.12%
Owned by Insiders (%)	5.01%
Owned by Institutions (%)	8.07%
Float	36.13M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.80
Forward PS	2.08
PB Ratio	3.48
P/TBV Ratio	5.01
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.31
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.24

Current Ratio	3.24
Quick Ratio	3.20
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -152.46% and return on invested capital (ROIC) is -56.43%.

Return on Equity (ROE)	-152.46%
Return on Assets (ROA)	-46.90%
Return on Invested Capital (ROIC)	-56.43%
Return on Capital Employed (ROCE)	-133.27%
Revenue Per Employee	$610,667
Profits Per Employee	-$3.20M
Employee Count	18
Asset Turnover	0.24
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -55.21% in the last 52 weeks. The beta is 0.27, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	-55.21%
50-Day Moving Average	0.99
200-Day Moving Average	1.24
Relative Strength Index (RSI)	37.61
Average Volume (20 Days)	252,300

Short Selling Information

The latest short interest is 136,163, so 0.30% of the outstanding shares have been sold short.

Short Interest	136,163
Short Previous Month	685,446
Short % of Shares Out	0.30%
Short % of Float	0.38%
Short Ratio (days to cover)	3.44

Income Statement

In the last 12 months, Opus Genetics had revenue of $10.99 million and -$57.53 million in losses. Loss per share was -$2.15.

Revenue	10.99M
Gross Profit	-15.86M
Operating Income	-34.07M
Pretax Income	n/a
Net Income	-57.53M
EBITDA	-34.06M
EBIT	-34.07M
Loss Per Share	-$2.15

Full Income Statement

Balance Sheet

The company has $30.32 million in cash and n/a in debt, giving a net cash position of $30.32 million or $0.67 per share.

Cash & Cash Equivalents	30.32M
Total Debt	n/a
Net Cash	30.32M
Net Cash Per Share	$0.67
Equity (Book Value)	25.57M
Book Value Per Share	0.21
Working Capital	25.32M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-25.58M
Capital Expenditures	n/a
Free Cash Flow	-25.58M
FCF Per Share	-$0.56

Full Cash Flow Statement

Margins

Gross Margin	-144.28%
Operating Margin	-309.99%
Pretax Margin	-523.40%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-23.74%
Shareholder Yield	-23.74%
Earnings Yield	-170.65%
FCF Yield	-75.86%

Analyst Forecast

The average price target for Opus Genetics is $7.00, which is 844.41% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.00
Price Target Difference	844.41%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Opus Genetics has an Altman Z-Score of -4.84 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.84
Piotroski F-Score	1